Lymphoma section

Featured Lymphoma Content

Recent Advances in Management of Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma

Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss the clinical treatment options for patients with relapsed Hodgkin lymphoma and anaplastic large cell lymphoma.

Lymphoma News and Features

R-THP-COP a New Therapeutic Alternative for Diffuse Large B Cell Lymphoma

R-THP-COP a New Therapeutic Alternative for Diffuse Large B Cell Lymphoma

Results of a prospective phase 3 study demonstrated noninferiority of R-THP-COP for diffuse large B cell lymphoma to the standard of care, suggesting the regimen may be an alternative option for these patients.

Dual Inhibitor for Treating CLL/SLL, Follicular Lymphoma Granted Priority Review

Dual Inhibitor for Treating CLL/SLL, Follicular Lymphoma Granted Priority Review

Duvelisib, a first-in-class dual inhibitor of PI3K-delta and -gamma, was evaluated in patients with relapsed/refractory CLL/SLL and in patients with refractory indolent non-Hodgkin lymphoma.

PET Use May Allow Early Treatment Adjustment in Non-Hodgkin Lymphoma

PET Use May Allow Early Treatment Adjustment in Non-Hodgkin Lymphoma

The ability to make early adjustments to treatment has the potential to improve survival.

Nurse-led Interventions Improve Quality of Life for Lymphoma Survivors

Nurse-led Interventions Improve Quality of Life for Lymphoma Survivors

Patients with lymphoma were interviewed to determine their evaluation of a program that offered continuing clinical care with a nurse-led intervention in the early months of survivorship.

Management of Relapsed/Refractory Marginal Zone Lymphoma: Focus on Ibrutinib

Management of Relapsed/Refractory Marginal Zone Lymphoma: Focus on Ibrutinib

[Cancer Management and Research] A review of marginal zone lymphomas, a common and varied group of hematologic malignancies, and their treatment, with a focus on the Bruton's tyrosine kinase ibrutinib.

Long-term Survival Improving Over Time in Advanced Hodgkin Lymphoma

Long-term Survival Improving Over Time in Advanced Hodgkin Lymphoma

A review of SEER data revealed trends in incidence of advanced Hodgkin lymphoma, discrepancies among subgroups, and survival over 3 decades.

Fifth Indication for Brentuximab Vedotin Is a First for cHL Therapy in 40+ Years

Fifth Indication for Brentuximab Vedotin Is a First for cHL Therapy in 40+ Years

FDA approval was granted based on findings from the open-label phase 3 ECHELON-1 study.

18F-FDG PET/CT Accurately Identifies Bone Marrow Involvement in Pediatric Hodgkin's Lymphoma

18F-FDG PET/CT Accurately Identifies Bone Marrow Involvement in Pediatric Hodgkin's Lymphoma

Researchers conducted a retrospective study to assess 18F-FDG PET/CT vs bone marrow biopsy to detect bone marrow involvement among pediatric patients with Hodgkin lymphoma.

Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma

Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma

In a case-control study using PEDS data, researchers determined the impact of inactivity on risk for Hodgkin lymphoma and non-Hodgkin lymphoma.

Complementary and Alternative Medicine Practices of Lymphoma Survivors in South Korea

Complementary and Alternative Medicine Practices of Lymphoma Survivors in South Korea

A study from South Korea determined the prevalence and type of CAM practices lymphoma survivors used for various purposes including ease symptoms, augment treatment, boost immunity, and gain a sense of control.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs